Marksans Pharma Share Price

Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.

The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.

Business operations

Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.

In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.

Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.

Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.

The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.

Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.

In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.

Financial Highlights

– Marksans Pharma’s revenue from operations for FY23 stood at ₹1,852 crore, up by 24.2% compared to ₹1,491 crore in FY22. – The net profit after tax for FY23 was ₹265.3 crore compared to ₹186.8 crore during the previous year. – In FY23, EBITDA increased to ₹339.3 crore from the previous year's ₹258.9 crore. – The company's earnings per share (EPS) stood at ₹6.4 in FY23 compared to ₹4.5 in the previous financial year.

Marksans Pharma Share Price Today

As of 26 May 2026, Marksans Pharma share price is ₹220.26. The stock opened at ₹214.00, compared to its previous close of ₹211.86. During today's trading session, Marksans Pharma share price moved in the range of ₹213.97 to ₹221.35, with an average price of ₹217.66 for the day. Looking at its last 52-week, the stock has touched a low of ₹213.97 and a high of ₹221.35. On the performance front, Marksans Pharma share price has increased by 16.82% over the last six months and is down 10.71% on a year-on-year basis.

The market capitalization of Marksans Pharma is ₹9,591 Crs, with a P/E ratio of 26.5 and a dividend yield of 0.38%.